Cargando…

Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer

The present study aimed at investigating whether the simultaneous evaluation of pharmacokinetic, pharmacogenetic and demographic factors could improve prediction on toxicity and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil (5FU)/leucovorin therapy. One hundred and thir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gusella, M, Frigo, A C, Bolzonella, C, Marinelli, R, Barile, C, Bononi, A, Crepaldi, G, Menon, D, Stievano, L, Toso, S, Pasini, F, Ferrazzi, E, Padrini, R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696766/ https://www.ncbi.nlm.nih.gov/pubmed/19384296 http://dx.doi.org/10.1038/sj.bjc.6605052

Ejemplares similares

Predicting steady‐state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable?
por: Gusella, Milena, et al.
Publicado: (2020)

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
por: Milano, G, et al.
Publicado: (1999)

Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study
por: De Placido, S, et al.
Publicado: (2005)

Systematic review and meta-analysis of tumour microsatellite-instability status as a predictor of response to fluorouracil-based adjuvant chemotherapy in colorectal cancer
por: Aggarwal, Nikhil, et al.
Publicado: (2021)

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
por: Glimelius, B, et al.
Publicado: (2011)

Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer
por: Malesci, Alberto, et al.
Publicado: (2017)

Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer
por: Holma, Reetta, et al.
Publicado: (2020)

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy
por: Amstutz, Ursula, et al.
Publicado: (2008)

In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
por: Kwon, Hye Youn, et al.
Publicado: (2016)

GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy
por: Wang, Zaozao, et al.
Publicado: (2014)

Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer
por: Hamaya, Yasushi, et al.
Publicado: (2015)

Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
por: Scheithauer, W., et al.
Publicado: (1998)

Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study
por: Lund, C M, et al.
Publicado: (2016)

Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil
por: Tebbutt, N C, et al.
Publicado: (2003)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer
por: Tajima, Yosuke, et al.
Publicado: (2017)

BZD9L1 sirtuin inhibitor as a potential adjuvant for sensitization of colorectal cancer cells to 5-fluorouracil
por: Tan, Yi Jer, et al.
Publicado: (2019)

Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis
por: Li, Qiang, et al.
Publicado: (2014)

Adjuvant 5-fluorouracil plus levamisole in colon cancer: the plot thickens?
por: Cassidy, J.
Publicado: (1994)

Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
por: Tsavaris, Nicolas, et al.
Publicado: (2008)

Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
por: Tsavaris, Nicolas, et al.
Publicado: (2009)

Predicting the effect of 5‐fluorouracil–based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles
por: Chen, Quan, et al.
Publicado: (2020)

Encephalopathy, lactic acidosis, hyperammonaemia and 5-fluorouracil toxicity.
por: Valik, D.
Publicado: (1998)

Influence of the skeletal muscle index on pharmacokinetics and toxicity of fluorouracil
por: Schmulenson, Eduard, et al.
Publicado: (2022)

Retracted: Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis
por: Research and Practice, Gastroenterology
Publicado: (2020)

Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity
por: Fidai, Shiraz S., et al.
Publicado: (2018)

Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Alliot, C
Publicado: (2006)

The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer.
por: Nichols, P. H., et al.
Publicado: (1994)

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
por: Sobrero, A, et al.
Publicado: (2005)

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
por: Sobrero, A, et al.
Publicado: (2005)

Optimal Duration of Fluorouracil-Based Adjuvant Chemotherapy for Patients with Resectable Gastric Cancer
por: Qu, Jing-lei, et al.
Publicado: (2013)

Thymidylate synthase polymorphism and survival of colorectal cancer patients treated with 5-fluorouracil
por: Ulrich, C M, et al.
Publicado: (2002)

The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
por: Goldberg, J. A., et al.
Publicado: (1990)

The effect of propolis on 5-fluorouracil-induced cardiac toxicity in rats
por: Barary, Mohammad, et al.
Publicado: (2022)

Reproductive and developmental toxicities of 5-fluorouracil in model organisms and humans
por: Naren, Gerile, et al.
Publicado: (2022)

Epigenetic alteration: new insights moving from tissue to plasma – the example of PCDH10 promoter methylation in colorectal cancer
por: Danese, E, et al.
Publicado: (2013)

Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
por: KÃ¶hne, C. H., et al.
Publicado: (1998)

Overexpression of CREPT confers colorectal cancer sensitivity to fluorouracil
por: Kuang, Yan-Shen, et al.
Publicado: (2018)

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_gnsqubaivj6kim2trknqv9hjho